Neil Howard Segal
Memorial Sloan Kettering Cancer Center · 345 works · 30,214 citations · h-index 64
Top works
- Nivolumab plus Ipilimumab in Advanced Melanoma
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- Epitope Landscape in Breast and Colorectal Cancer
- Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy
- PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer
- Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
- Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
- Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).
- Immunotherapy in colorectal cancer: rationale, challenges and potential
- Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy
- CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
- Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1
- Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer
- Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer
- Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer
- Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy
- EWS-CREB1 : A Recurrent Variant Fusion in Clear Cell Sarcoma—Association with Gastrointestinal Location and Absence of Melanocytic Differentiation
- Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody.
- Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC).
- Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial